World First: Quintessence Biotech reinvents bio-separation to remove the manufacturing bottleneck that has kept cell and gene therapy available to only 1% of eligible patients. CGT can finally become a standard of care.

• Up to 60% reduction in cost of goods (COGS) through radical process simplification
• 12× more therapeutic doses produced per site
• Doubling therapeutic efficacy, thus drastically reducing the risk of side effects and relapse

Cell and gene therapies (CGT) have demonstrated remarkable clinical success with eligible patient pools expanding rapidly beyond initial rare disease applications. Yet today, fewer than 1% of eligible patients have access to them, due to limited industrialization largely constrained by bio-separation technologies dating back to the 1990s. Quintessence Biotech reinvents this core process with a biological reagent capable of reproducing natural processes while simplifying industrial workflows. This breakthrough improves therapeutic efficacy, significantly reducing manufacturing costs, while working seamlessly with existing cell culture hardware. By transforming manufacturing at its foundation, Quintessence Biotech unlocks industrial-scale production of living medicines — making them accessible to millions of patients worldwide. Welcome to the new era of biological therapies, where nature and engineering finally converge.

A New Era in Cell Therapy Manufacturing…

Cell therapies are based on a simple and powerful idea: using living cells as medicine. Instead of treating diseases with chemical molecules, these therapies reactivate the body’s natural defenses to fight cancers and pathogens or restore tissue. With over 4,000 cell and gene therapy drugs currently in development worldwide, the field is rapidly expanding beyond blood cancers into solid tumors, autoimmune diseases, and regenerative medicine. As manufacturing becomes more flexible and scalable, the potential impact is enormous: within the next decade, cell therapy could treat up to five million patients each year. Manufacturing must evolve to keep pace.

Indeed, scaling cell and gene therapy is not simply a question of demand, it is a question of manufacturing infrastructure. Because bio-separation sits at the core of the manufacturing process, it effectively determines cost, performance, and scalability. Current solutions concentrate supplier power, and force developers into rigid production models that are neither economically sustainable nor adapted to modern therapeutic challenges. As a result, treatment efficacy is compromised, with relapse rates reaching up to 50 percent and severe side effects linked to current manufacturing methods.

Removing this bottleneck is not an incremental improvement. It is a structural shift required for cell therapy to become a standard of care. This is precisely what Quintessence Biotech addresses.

…Thanks to a New Process of Bio-Separation…

“Our mission is simple: to take inspiration from Nature and make living medicines available to everyone, everywhere. At Quintessence Biotech, we have shifted bio-separation from a mechanical constraint into a biological enabler. This revolution makes industrial-scale production of cell therapies economically and operationally viable. It allows more patients to access treatments once confined to small clinical trials and accelerates the transition from breakthrough science to standard of care”, explains Charles Cavaniol, PhD, co-founder and CEO of Quintessence Biotech.

Quintessence Biotech puts an end to mechanical separation through radical simplification. Legacy magnetic beads are replaced by a biomimetic reagent, allowing both a simplified cell separation and induced physiological activation, integrating seamlessly into existing cell culture systems. Where current bio-separation relies on expensive components and unnatural mechanical processes, Quintessence Biotech’s artificial living cell simplify workflows while improving outcomes.

…Which Reduces Cost by Radically Simplifying…

The impact spans the entire manufacturing chain: fewer manual steps, reduced equipment dependency, shorter timelines from R&D to commercial production, and elimination of early hardware lock-in. The solution fits operational reality. It scales without redesign. It preserves therapeutic efficacy. Plug-and-play, the same reagent can be used from laboratory development through commercial-scale manufacturing, without additional infrastructure investment.

… And Improves Efficacy and Greater Versatility

Five million people worldwide could benefit from a new path toward more patients and fewer relapses, thanks to more effective therapies. By reproducing natural processes, we enable twofold increase in therapeutic cell functionality, drastically reduces the risk of side effect and relapse.

The impact of Quintessence Biotech goes beyond current treatments. The improvement in viability and potency of therapeutic cells opens the door to new therapies: oncology on solid tumors, autoimmune and regenerative medicine.

Commercial Traction and Operational Validation

Quintessence Biotech is moving fast. In less than a year, the company demonstrated commercial viability through a twelve-month progression from laboratory technology to functioning production, with two customer-validated products supporting 2027 clinical trial therapies, which will represent 20.000 patients that be cured, five signed contracts, ten active partnerships, and thirty global leads. The company established production delivering 100 monthly kits with products meeting sterility and traceability requirements toward GMP compliance.

How It Works: The First Artificial Cell Inspired by Nature

The company’s proprietary innovation DACS^TM is based on a buoyant biomimetic lipid particle technology, derived from the pioneering work of Ass. Prof. Jacques Fattaccioli (ENS, ESPCI, Université PSL). This lipid emulsion reproduces the essential properties of a human cell-size, flexibility, molecular interactions, and combines two major innovations:

• Flotation based Bioseparation. These enable an unprecedented level of manufacturing simplicity, drastically reducing the number of steps and dependency on specialized equipment.
• Artificial antigen-presenting cell (aAPC) characteristics. These allow physiological and controlled activation of therapeutic cells, recreating an environment close to natural biology.

“Our approach transforms constraints into advantages. Where magnetic particles force early hardware choices, our buoyant lipid droplet flexibility enables optimization across development-to-production. Where current bio-separation requires expensive specialized components and unnatural mechanical processes, Quintessence Biotech’s single use reagents simplify workflows while improving outcomes. The solution addresses therapeutic developer reality: manufacturing tools working simply in technician-operated production, scaling without redesign, improving therapeutic efficacy. CGT can finally become an accessible commodity transforming medicine.” explains Dr. Mathieu Gonçalves-Venturelli, co-founder and CSO of Quintessence Biotech.

To access visuals, please click here.

About Quintessence Biotech

Quintessence Biotech is a French deeptech biotechnology company focused on making cell and gene therapy available to everyone, everywhere, by reinventing bio-separation. The company has developed its DACS^TM technology based on a universal biomimetic lipid droplet platform that replaces traditional mechanical separation technologies with a biologically inspired, reagent-based approach. By simultaneously reducing manufacturing complexity and preserving cell functionality, Quintessence Biotech enables significant cost reduction and improved therapeutic performance, making advanced cell and gene therapies economically viable at commercial scale. The platform builds on the pioneering scientific work of Ass. Prof. Jacques Fattaccioli (ENS, ESPCI, Sorbonne) and is supported by leading innovation institutions including Ecole Normale Superieure Paris, PSL University, Agoranov, WILCO, Sorbonne University, Medicen, PMT Santé, Région Ile-de-France, Paris Saclay Cancer Cluster and Bpifrance. Founded in December 2024 by Charles Cavaniol (CEO), Mathieu Gonçalves-Venturelli (CSO), and Aurélien Lepoetre (CTO) and Jacques Fattaccioli, Quintessence Biotech combines deep expertise in cell therapy manufacturing, industrial development, and commercialization to build the infrastructure foundation for next-generation living medicines.

https://www.quintessence-biotech.com/